KORU Medical Systems, Inc. - 8-K Filing Summary
Business Context and Reporting Period
KORU Medical Systems, Inc. (KRMD) filed a Current Report on Form 8-K on March 12, 2026. The filing announces the Company's financial results for the fourth fiscal quarter and the full year ended December 31, 2025, along with financial guidance for the fiscal year ending December 31, 2026.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
The Company utilizes the following non-GAAP financial measures to supplement GAAP results:
- Adjusted EBITDA: Defined as net income/loss before tax benefits/allowances, interest, depreciation and amortization, reorganization charges, tax expense, and stock-based compensation.
- Adjusted Diluted EPS: Reported diluted earnings per share adjusted for tax items, depreciation and amortization, reorganization charges, and stock-based compensation to reflect ordinary operations.
Material Changes
The filing text does not disclose specific material changes in financial performance versus prior periods. Investors are directed to the attached press release (Exhibit 99.1) for a reconciliation of GAAP to non-GAAP results and detailed operational comparisons.
Guidance, Outlook, and Management Commentary
Management has issued financial guidance for the fiscal year ended December 31, 2026. A conference call to discuss these results and the outlook was scheduled for March 12, 2026, at 4:30 pm Eastern Time. Management emphasizes that non-GAAP measures should be read in conjunction with GAAP financial statements and may differ from similar measures used by other companies.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and Full Year 2025.
- Examine the reconciliation table in the press release to understand the adjustments made to derive Adjusted EBITDA and Adjusted Diluted EPS.
- Verify the specific numerical targets provided in the 2026 financial guidance.
- Assess the impact of reorganization charges and stock-based compensation on reported earnings.